-
Treatment form of severe head and neck cancer ushered in immunotherapy, its five-year survival rate is about to be refreshed
Time of Update: 2021-01-24
The latest statistics show that cancer deaths account for 23.91% of all deaths in China, and cancer has become one of the major public health problems that seriously threaten the health of residents.
-
Professor Chen Minshan: Annual inventory of progress in liver cancer treatment in 2020
Time of Update: 2021-01-24
This year's major international conferences published several advances in research on complementary and conversion therapy, including a new study of complementary therapy published at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO) on 30 patients with liver cancer that could be removed at the beginning of the treatment, using three cycles of Navuliyu monotherapy or navu before surgery.
-
J Clin Oncol: Can high-risk bowel cancer be reduced to 3 months to reduce neurotoxicity with Osali platinum treatment?
Time of Update: 2021-01-23
patients included in the analysis were treated with fluorouracil, folate and oxalipoli (FOLFOX) or capedabin and oxaliplatin (CAPOX) and were randomly assigned to the March or June treatment group.
-
High coffee intake may be associated with a low risk of prostate cancer
Time of Update: 2021-01-23
recently, a new paper published on BMJ Open conducted a meta-analysis of these queue studies, a systematic review of the relationship between coffee intake and prostate cancer risk.
-
Lancet oncol: Can endocrine therapy with Pabosinib further improve prognostication in patients with early breast cancer?
Time of Update: 2021-01-23
PALAS trial was designed to investigate whether pabosinib, which was added for 2 years in assisted endocrine therapy, could further improve the survival rate of hormone-positive, HER2-negative early breast cancer patients with non-invasive diseases compared to endocrine therapy alone.
-
J Immunother Cancer: The rate of venous thromboembolism in patients with melanoma treated with immuno-checkpoint inhibitors
Time of Update: 2021-01-23
rates of arterial TE (ATE) and venous TE (VTE) in melanoma patients treated with immunosuppressants (ICI) are not clear.
the cumulative rate of VTE at 6 and 12 months of combined ICI therapy was higher than that of single-drug therapy (16.7% vs 5.0% and 21.3% vs 9.5%).
-
JAMA Oncol: Phase 3 randomized trial | Sequentia chemotherapy vs simultaneous chemotherapy is used as an early postoperative ancillary treatment for cervical cancer
Time of Update: 2021-01-23
SCRT treatment also reduces the risk of cancer death compared to RT (five-year survival rate: 92.0% vs 88.0%; HR 0.58, 95% CI 0.35-0.95).
, the study showed that SCRT treatments improved DFS rates and reduced the risk of cancer death compared to CCRT for early cervical cancer patients.
-
Japan's five-year survival rate of stomach cancer as high as 80%, China's only 30%, why the gap is so big?
Time of Update: 2021-01-23
Recently, the World Health Organization's International Agency for Research on Cancer released the Chinese Chinese "Global Cancer Burden Data 2020", China's data are particularly striking, in 2020, th
-
Prof. Chen Jie: 2020, My NET Road
Time of Update: 2021-01-23
2020）。 , as well as our team's ultrasound and tumor intervention partners, are exploring all aspects of neuroendocrine cancer diagnosis and treatment from their own clinical perspectives.
-
Nat Commun: Mendel randomized analysis assesses the association between vitamin D and cancer susceptivity
Time of Update: 2021-01-23
vitamin D, whether produced or consumed in the skin, requires two hydroxylation steps to become an active form.
, the results suggest that a lower level of 25 (OH) D is unlikely to be a causal risk factor for most cancers, and the results provide a more accurate confidence interval than previous studies.
-
Eur J Cancer: The long-term follow-up prognosis for the treatment of advanced kidney cancer by Axithini combined with Pim single anti-treatment is good!
Time of Update: 2021-01-23
In a randomized Phase III trial, Axitinib and Pembrolizumab showed better overall survival (OS), progress-free survival (PFS) and objective response rates (ORR) than Sunitinib in patients with advanced kidney cancer.
-
Lancet Oncol: Ivosidenib significantly improved survival rates in patients with advanced mIDH1 bile tube cancer
Time of Update: 2021-01-23
patients with bile tube cancer in the ivosidenib group were treated with oral 500 mg ivosidenib per day; The main study endpoints of the trial were progress-free lifetime (PFS), and the secondary study endpoints were total lifetime (OS), objective response rate (ORR), reaction duration and reaction time (assessed by researchers and research centers); the main endpoint PFS, the ivosidenib group: the placebo group was 2.7 months: 1.4 months (HR-0.37, 95% CI:0.25-0.54, p-lt;0.001).
-
J Immunother Cancer: The efficacy and safety of the treatment of relapsed small± cell lung cancer with stereotactic body radiotherapy
Time of Update: 2021-01-23
patients with relapsed SCLC who had previously treated no more than 2 lines were randomly assigned to Group A: Durvalumab (D) 1500/Tremlimumab, T) 75 mg (intravenous injection every 4 weeks, no SBRT); Group B: Select a tumor site for immunosensitive SBRT (9Gy×3 times), followed by D/T treatment until the disease progresses or reaches 12 months.
-
DB102 (Enzastaurin) Treatment of Primary Glioblastoma (GBM): Phase III clinical trials have been initiated
Time of Update: 2021-01-23
pharmaceutical company Denovo Biopharma announced today that the first patient in a Phase III clinical study has been treated to assess the effectiveness and safety of DB102 (enzastaurin) in combination with termosamine/radiotherapy as a first-line therapy for the initial treatment of polymorphic glioblastoma (GBM).
-
U.S. Cancer Statistics 2021: 1.89 million new cases and 600,000 deaths, the second year in a row that the death rate has dropped sharply
Time of Update: 2021-01-23
women have a higher rate of non-smoking-related lung cancer than men, smoking remains the leading preventable cause of death in the United States, costing more than $300 billion a year.
-
JAMA Netw Open: Where is the future of telemedicme?
Time of Update: 2021-01-23
addition, several studies have shown that tele-care can improve access to cancer care for patients in rural areas, while at the same time providing patients with the same or better satisfaction and cost savings than in-person visits.
-
Nat Commun: In-tumor immune heterogeneity (ITH): a sign of the development of hepatocellular carcinoma and tumor evolution
Time of Update: 2021-01-23
researchers found important spatial and esopic immune ITH in multiple tumor sites and explained its relationship to tumor evolution and disease development in the HCC.
-
Eur Radiol: How does metastasis occur in front of non-small cell lung cancer patients without invasive accuracy?
Time of Update: 2021-01-23
A paper published recently on Eur Radiol called Machine learning-based diagnostic method of pre-18 F-FDG PET/CT for evaluating mediastinal lymph nodes in non-cell lung cancer by using 18F-fluoride deoxygenated glucose (FDG) electron emission fault scanning/computer fault scanning (PET/CT) establishes the best machine learning (ML) model to evaluate metastatic lymph nodes (MedLNs) of non-small cell lung cancer and compare the diagnosis with that of a nuclear medicine physician.
-
Eur J Cancer: The clinical benefits of ctDNA as a biomarker for stage 4 colorectal cancer
Time of Update: 2021-01-23
For patients with metastatic colorectal cancer, strated therapy (surgery or chemotherapy) is usually based on rough clinical pathological characteristics, such as tumor size and number of lesions.
through literature search, screening studies on IV.stage colorectal cancer ctDNA testing and clinical prognostofectomy (radiotherapy response, secondary excision rate, PFS, DFS, or OS).
-
Heavy discovery | God's journal CA announces the reasons for the decline in cancer deaths in the United States!
Time of Update: 2021-01-23
although the risk of lung cancer from smoking was small, the incidence of non-smoking-related lung cancer was much higher in women than in men.
same time, the overall death rate in the United States fell by 7.7 percent between 2014 and 2018, 46 percent of which was due to lung cancer.
